BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017;28:34-43. [PMID: 28177494 DOI: 10.1093/annonc/mdw413] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 32.5] [Reference Citation Analysis]
Number Citing Articles
1 Woolacott N, Corbett M, Jones-diette J, Hodgson R. Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. Journal of Clinical Epidemiology 2017;90:108-18. [DOI: 10.1016/j.jclinepi.2017.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
2 London AJ, Kimmelman J. Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. Hastings Center Report 2019;49:31-41. [DOI: 10.1002/hast.1034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
3 Mathoulin-Pélissier S, Pritchard-Jones K. Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation. Eur J Surg Oncol 2019;45:22-30. [PMID: 29526369 DOI: 10.1016/j.ejso.2018.02.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
4 Kakoki K, Miyata Y, Mochizuki Y, Iwata T, Obatake M, Abe K, Nagayasu T, Sakai H. Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical Genitourinary Cancer 2017;15:e503-6. [DOI: 10.1016/j.clgc.2016.12.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
5 Collignon O, Schritz A, Spezia R, Senn SJ. Implementing Historical Controls in Oncology Trials. Oncologist 2021;26:e859-62. [PMID: 33523511 DOI: 10.1002/onco.13696] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhou T, Ji Y. RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics 2021;22:897-912. [PMID: 32061093 DOI: 10.1093/biostatistics/kxaa005] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wagholikar KB, Fischer CM, Goodson AP, Herrick CD, Maclean TE, Smith KV, Fera L, Gaziano TA, Dunning JR, Bosque-Hamilton J, Matta L, Toscano E, Richter B, Ainsworth L, Oates MF, Aronson S, MacRae CA, Scirica BM, Desai AS, Murphy SN. Phenotyping to Facilitate Accrual for a Cardiovascular Intervention. J Clin Med Res 2019;11:458-63. [PMID: 31143314 DOI: 10.14740/jocmr3830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hazim A, Prasad V. A pooled analysis of published, basket trials in cancer medicine. European Journal of Cancer 2018;101:244-50. [DOI: 10.1016/j.ejca.2018.06.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
9 Hayashi H, Tanishima S, Fujii K, Mori R, Okada C, Yanagita E, Shibata Y, Matsuoka R, Amano T, Yamada T, Yabe I, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. Cancer Sci 2020;111:3926-37. [PMID: 32772458 DOI: 10.1111/cas.14608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Keam B, Kim HR, Yun HJ. TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer. Cancer Res Treat 2019;51:413-4. [PMID: 30064199 DOI: 10.4143/crt.2018.335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A, Wright K, Cantrell A, Stevenson M, Palmer S. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess 2021;25:1-228. [PMID: 34990339 DOI: 10.3310/hta25760] [Reference Citation Analysis]
12 Park JJH, Ford N, Xavier D, Ashorn P, Grais RF, Bhutta ZA, Goossens H, Thorlund K, Socias ME, Mills EJ. Randomised trials at the level of the individual. Lancet Glob Health 2021;9:e691-700. [PMID: 33865474 DOI: 10.1016/S2214-109X(20)30540-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Li A, Bergan RC. Clinical trial design: Past, present, and future in the context of big data and precision medicine. Cancer 2020;126:4838-46. [PMID: 32931022 DOI: 10.1002/cncr.33205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
14 Couwenberg A, van der Heide U, Janssen T, van Triest B, Remeijer P, Marijnen C, Sonke JJ, Nowee M. Master protocol trial design for technical feasibility of MR-guided radiotherapy. Radiother Oncol 2021;166:33-6. [PMID: 34785244 DOI: 10.1016/j.radonc.2021.11.009] [Reference Citation Analysis]
15 Snowdon C, Kernaghan S, Moretti L, Turner NC, Ring A, Wilkinson K, Martin S, Foster S, Kilburn LS, Bliss JM. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials 2022;23:372. [PMID: 35526005 DOI: 10.1186/s13063-022-06312-x] [Reference Citation Analysis]
16 Fortpied C, Vinches M. The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. Front Oncol 2019;9:634. [PMID: 31355146 DOI: 10.3389/fonc.2019.00634] [Reference Citation Analysis]
17 Takeda K, Liu S, Rong A. Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. Stat Med 2021. [PMID: 34697822 DOI: 10.1002/sim.9237] [Reference Citation Analysis]
18 Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, Lester RT, Thorlund K, Mills EJ. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019;20:572. [PMID: 31533793 DOI: 10.1186/s13063-019-3664-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 21.0] [Reference Citation Analysis]
19 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020;6:e12050. [PMID: 32695874 DOI: 10.1002/trc2.12050] [Cited by in Crossref: 66] [Cited by in F6Publishing: 79] [Article Influence: 33.0] [Reference Citation Analysis]
20 Kaizer AM, Hobbs BP, Koopmeiners JS. A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. Biometrics 2018;74:1082-94. [PMID: 29359450 DOI: 10.1111/biom.12841] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
21 Lévy V. Of some innovations in clinical trial design in hematology and oncology. Therapie 2021:S0040-5957(21)00245-6. [PMID: 34922739 DOI: 10.1016/j.therap.2021.10.011] [Reference Citation Analysis]
22 Sequiera GL, Srivastava A, Sareen N, Yan W, Alagarsamy KN, Verma E, Aghanoori MR, Aliani M, Kumar A, Fernyhough P, Rockman-Greenberg C, Dhingra S. Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. Sci Adv 2022;8:eabl4370. [PMID: 35394834 DOI: 10.1126/sciadv.abl4370] [Reference Citation Analysis]
23 Bogin V. Master protocols: New directions in drug discovery. Contemp Clin Trials Commun 2020;18:100568. [PMID: 32395664 DOI: 10.1016/j.conctc.2020.100568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Hague D, Townsend S, Masters L, Rauchenberger M, Van Looy N, Diaz-Montana C, Gannon M, James N, Maughan T, Parmar MKB, Brown L, Sydes MR; STAMPEDE and FOCUS4 investigators. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. Trials 2019;20:294. [PMID: 31138292 DOI: 10.1186/s13063-019-3322-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
25 Siden EG, Park JJ, Zoratti MJ, Dron L, Harari O, Thorlund K, Mills EJ. Reporting of master protocols towards a standardized approach: A systematic review. Contemp Clin Trials Commun 2019;15:100406. [PMID: 31334382 DOI: 10.1016/j.conctc.2019.100406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
26 Stallard N, Todd S, Parashar D, Kimani PK, Renfro LA. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Ann Oncol 2019;30:506-9. [PMID: 30715156 DOI: 10.1093/annonc/mdz038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
27 Hung MH, Wang XW. Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 293-316. [DOI: 10.1007/978-3-030-21540-8_14] [Reference Citation Analysis]
28 Williams E, Brown TJ, Griffith P, Rahimi A, Oilepo R, Hammers H, Laetsch TW, Currykosky P, Partridge S, Beg MS. Improving the Time to Activation of New Clinical Trials at a National Cancer Institute–Designated Comprehensive Cancer Center. JCO Oncology Practice 2020;16:e324-32. [DOI: 10.1200/op.19.00325] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Habermehl C, Benner A, Kopp-Schneider A. Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction. Biom J 2018;60:275-87. [PMID: 28762532 DOI: 10.1002/bimj.201600226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Yin G, Yang Z, Odani M, Fukimbara S. Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. Statistics in Biopharmaceutical Research 2021;13:248-58. [DOI: 10.1080/19466315.2020.1811146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Brooks PJ, Ottinger EA, Portero D, Lomash RM, Alimardanov A, Terse P, Xu X, Chandler RJ, Geist Hauserman J, Esposito E, Bönnemann CG, Venditti CP, Austin CP, Pariser A, Lo DC. The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup. Hum Gene Ther 2020;31:1034-42. [PMID: 32993373 DOI: 10.1089/hum.2020.259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Speers MA. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. Pharm Med 2019;33:89-98. [DOI: 10.1007/s40290-019-00274-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Bunn V, Liu R, Lin J, Lin J. Flexible Bayesian subgroup analysis in early and confirmatory trials. Contemp Clin Trials 2020;98:106149. [PMID: 32942055 DOI: 10.1016/j.cct.2020.106149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Sotelo-Rodríguez DC, Ruíz-Patiño A, Ricaurte L, Arrieta O, Zatarain-Barrón ZL, Cardona AF. Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalscience 2019;13:936. [PMID: 31552109 DOI: 10.3332/ecancer.2019.936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Merrill NM, Lachacz EJ, Vandecan NM, Ulintz PJ, Bao L, Lloyd JP, Yates JA, Morikawa A, Merajver SD, Soellner MB. Molecular determinants of drug response in TNBC cell lines. Breast Cancer Res Treat 2020;179:337-47. [PMID: 31655920 DOI: 10.1007/s10549-019-05473-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Mulcahey MJ, Jones LAT, Rockhold F, Rupp R, Kramer JLK, Kirshblum S, Blight A, Lammertse D, Guest JD, Steeves JD. Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system. Spinal Cord 2020;58:1235-48. [DOI: 10.1038/s41393-020-00547-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Dooms M, Saesen R, Steemans I, Lansens J, Huys I. Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders. Front Pharmacol 2022;13:775217. [DOI: 10.3389/fphar.2022.775217] [Reference Citation Analysis]
38 Bitterman DS, Cagney DN, Singer LL, Nguyen PL, Catalano PJ, Mak RH. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. J Natl Cancer Inst 2020;112:229-37. [PMID: 31504680 DOI: 10.1093/jnci/djz167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
39 Fiorino C, Jeraj R, Clark CH, Garibaldi C, Georg D, Muren L, van Elmpt W, Bortfeld T, Jornet N. Grand challenges for medical physics in radiation oncology. Radiotherapy and Oncology 2020;153:7-14. [DOI: 10.1016/j.radonc.2020.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
40 Liao JJ, Liu GF. A flexible parametric survival model for fitting time to event data in clinical trials. Pharmaceutical Statistics 2019;18:555-67. [DOI: 10.1002/pst.1947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Caparrotta TM, Dear JW, Colhoun HM, Webb DJ. Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. Br J Clin Pharmacol 2019;85:1907-24. [PMID: 31206748 DOI: 10.1111/bcp.14024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
42 Polley MC, Cheung YK. Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology. JCO Precis Oncol 2019;3:PO. [PMID: 32923846 DOI: 10.1200/PO.19.00057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Bando H. The current status and problems confronted in delivering precision medicine in Japan and Europe. Curr Probl Cancer 2017;41:166-75. [PMID: 28391973 DOI: 10.1016/j.currproblcancer.2017.02.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
44 Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H. Generating comparative evidence on new drugs and devices after approval. Lancet 2020;395:998-1010. [PMID: 32199487 DOI: 10.1016/S0140-6736(19)33177-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
45 Lavacchi D, Roviello G, D'Angelo A. Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clin Drug Investig 2020;40:519-27. [PMID: 32307639 DOI: 10.1007/s40261-020-00915-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
46 Dittrich C. Basket trials: From tumour gnostic to tumour agnostic drug development. Cancer Treatment Reviews 2020;90:102082. [DOI: 10.1016/j.ctrv.2020.102082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Iwasaki E, Fukuhara S, Horibe M, Kawasaki S, Seino T, Takimoto Y, Tamagawa H, Machida Y, Kayashima A, Noda M, Hayashi H, Kanai T. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics (Basel) 2021;11:469. [PMID: 33800161 DOI: 10.3390/diagnostics11030469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang HC, Chan LP, Wu CC, Hsiao HH, Liu YC, Cho SF, Du JS, Liu TC, Yang CH, Pan MR, Moi SH. Progression Risk Score Estimation Based on Immunostaining Data in Oral Cancer Using Unsupervised Hierarchical Clustering Analysis: A Retrospective Study in Taiwan. J Pers Med 2021;11:908. [PMID: 34575686 DOI: 10.3390/jpm11090908] [Reference Citation Analysis]
49 Miquel-cases A, Schouten PC, Steuten LM, Retèl VP, Linn SC, van Harten WH. (Very) Early technology assessment and translation of predictive biomarkers in breast cancer. Cancer Treatment Reviews 2017;52:117-27. [DOI: 10.1016/j.ctrv.2016.11.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
50 Cata JP, Forget P. Paravertebral block with propofol anaesthesia does not improve survival compared with sevoflurane anaesthesia for breast cancer surgery: independent discussion of a randomised controlled trial. British Journal of Anaesthesia 2020;124:19-24. [DOI: 10.1016/j.bja.2019.09.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Lorgelly PK, Adler A. Impact of a Global Pandemic on Health Technology Assessment. Appl Health Econ Health Policy 2020;18:339-43. [PMID: 32377982 DOI: 10.1007/s40258-020-00590-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
52 Krittanawong C, Bomback AS, Baber U, Bangalore S, Messerli FH, Wilson Tang WH. Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Curr Hypertens Rep 2018;20:75. [PMID: 29980865 DOI: 10.1007/s11906-018-0875-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
53 Dueck AC. A statistician's perspective on a long time to publish. Lancet Haematol 2017;4:e12. [PMID: 27916632 DOI: 10.1016/S2352-3026(16)30183-1] [Reference Citation Analysis]
54 Berry SA, Ghanem KG. Licensing Nucleic Acid Amplification Tests for Extragenital Gonorrhea and Chlamydia: Innovative Science and a Call to Arms. Clin Infect Dis 2020;71:2323-5. [PMID: 31872856 DOI: 10.1093/cid/ciz1110] [Reference Citation Analysis]
55 Sánchez NS, Mills GB, Mills Shaw KR. Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 2017;18:1525-39. [PMID: 29061079 DOI: 10.2217/pgs-2017-0094] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
56 Lee KM, Wason J. Design of experiments for a confirmatory trial of precision medicine. J Stat Plan Inference 2019;199:179-87. [PMID: 31007363 DOI: 10.1016/j.jspi.2018.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 2021;9:e002459. [PMID: 34215688 DOI: 10.1136/jitc-2021-002459] [Reference Citation Analysis]
58 London AJ. Learning health systems, clinical equipoise and the ethics of response adaptive randomisation. J Med Ethics 2018;44:409-15. [DOI: 10.1136/medethics-2017-104549] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
59 Verweij J, Hendriks H, Zwierzina H, Hanauske, Wacheck V, Collignon O, Bruzzi P, Gross J, Riehl T, Bretz F, Dollins, Radtke I. Innovation in oncology clinical trial design. Cancer Treatment Reviews 2019;74:15-20. [DOI: 10.1016/j.ctrv.2019.01.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
60 Sacristán JA, Knottnerus JA. Individual point-of-care trials: a new approach to incorporate patient's preferences into personalized pragmatic clinical trials. J Clin Epidemiol 2021;130:152-5. [PMID: 33002636 DOI: 10.1016/j.jclinepi.2020.09.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Brierley CK, Zabor EC, Komrokji RS, DeZern AE, Roboz GJ, Brunner AM, Stone RM, Sekeres MA, Steensma DP. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer 2020;126:4735-43. [PMID: 32767690 DOI: 10.1002/cncr.33105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Simonsen KL, Fracasso PM, Bernstein SH, Wind-Rotolo M, Gupta M, Comprelli A, Reilly TP, Cassidy J. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. Eur J Cancer 2018;103:259-66. [PMID: 30292142 DOI: 10.1016/j.ejca.2018.07.127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
63 Turner RM, Turkova A, Moore CL, Bamford A, Archary M, Barlow-mosha LN, Cotton MF, Cressey TR, Kaudha E, Lugemwa A, Lyall H, Mujuru HA, Mulenga V, Musiime V, Rojo P, Tudor-williams G, Welch SB, Gibb DM, Ford D, White IR; and the ODYSSEY Trial Team. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Med Res Methodol 2022;22. [DOI: 10.1186/s12874-022-01539-3] [Reference Citation Analysis]
64 Di Liello R, Piccirillo MC, Arenare L, Gargiulo P, Schettino C, Gravina A, Perrone F. Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials. Life (Basel) 2021;11:1253. [PMID: 34833129 DOI: 10.3390/life11111253] [Reference Citation Analysis]
65 Italiano A, Dinart D, Soubeyran I, Bellera C, Espérou H, Delmas C, Mercier N, Albert S, Poignie L, Boland A, Bourdon A, Geneste D, Cavaille Q, Laizet Y, Khalifa E, Auzanneau C, Squiban B, Truffaux N, Olaso R, Gerber Z, Wallet C, Bénard A, Blay JY, Laurent-Puig P, Deleuze JF, Lucchesi C, Mathoulin-Pelissier S; MULTISARC study group. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. BMC Cancer 2021;21:1180. [PMID: 34740331 DOI: 10.1186/s12885-021-08878-2] [Reference Citation Analysis]
66 Siu LL, Ivy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clin Cancer Res 2017;23:4950-8. [PMID: 28864723 DOI: 10.1158/1078-0432.CCR-16-3079] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
67 Zabor EC, Kane MJ, Roychoudhury S, Nie L, Hobbs BP. Bayesian basket trial design with false-discovery rate control. Clin Trials 2022;:17407745211073624. [PMID: 35128970 DOI: 10.1177/17407745211073624] [Reference Citation Analysis]
68 Collignon O, Gartner C, Haidich A, James Hemmings R, Hofner B, Pétavy F, Posch M, Rantell K, Roes K, Schiel A. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. Clin Pharmacol Ther 2020;107:1059-67. [DOI: 10.1002/cpt.1804] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
69 Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason JMS. Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. BMC Rheumatol 2021;5:21. [PMID: 34210348 DOI: 10.1186/s41927-021-00192-5] [Reference Citation Analysis]
70 Shi Y, Zhang W, Ye Y, Cheng Y, Han L, Liu P, Zhao W, Tong Z, Yu J. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway. Cancer Biol Med 2018;15:314-21. [PMID: 30197799 DOI: 10.20892/j.issn.2095-3941.2017.0188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. Ann Oncol 2018;29:2313-27. [PMID: 30307465 DOI: 10.1093/annonc/mdy452] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
72 Zheng H, Hampson LV, Jaki T. Bridging across patient subgroups in phase I oncology trials that incorporate animal data. Stat Methods Med Res 2021;30:1057-71. [PMID: 33501882 DOI: 10.1177/0962280220986580] [Reference Citation Analysis]
73 Lewis CJ, Sarkar S, Zhu J, Carlin BP. Borrowing from Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines. Stat Biopharm Res 2019;11:67-78. [PMID: 31435458 DOI: 10.1080/19466315.2018.1497533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
74 Zabor EC, Kaizer AM, Hobbs BP. Randomized Controlled Trials. Chest 2020;158:S79-87. [PMID: 32658656 DOI: 10.1016/j.chest.2020.03.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Park JJH, Dron L, Mills EJ. Moving forward in clinical research with master protocols. Contemp Clin Trials 2021;106:106438. [PMID: 34000408 DOI: 10.1016/j.cct.2021.106438] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Herrington WG, Staplin N, Haynes R. Kidney disease trials for the 21st century: innovations in design and conduct. Nat Rev Nephrol 2020;16:173-85. [PMID: 31673162 DOI: 10.1038/s41581-019-0212-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
77 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
78 Bernhardt J, Hayward KS, Dancause N, Lannin NA, Ward NS, Nudo RJ, Farrin A, Churilov L, Boyd LA, Jones TA, Carmichael ST, Corbett D, Cramer SC. A stroke recovery trial development framework: Consensus-based core recommendations from the Second Stroke Recovery and Rehabilitation Roundtable. International Journal of Stroke 2019;14:792-802. [DOI: 10.1177/1747493019879657] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
79 Ballarini NM, Burnett T, Jaki T, Jennison C, König F, Posch M. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. Stat Med 2021;40:2939-56. [PMID: 33783020 DOI: 10.1002/sim.8949] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin 2020;70:125-37. [PMID: 32031692 DOI: 10.3322/caac.21600] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
81 Nosrati M, Nikfar S. Conducting economic evaluation based on basket clinical trial in the area of precision medicine. Expert Rev Pharmacoecon Outcomes Res 2021;21:169-71. [PMID: 33356657 DOI: 10.1080/14737167.2021.1865158] [Reference Citation Analysis]
82 Lu CC, Li XN, Broglio K, Bycott P, Jiang Q, Li X, McGlothlin A, Tian H, Ye J. Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. Ther Innov Regul Sci 2021. [PMID: 34160785 DOI: 10.1007/s43441-021-00315-7] [Reference Citation Analysis]
83 Kaizer AM, Koopmeiners JS, Chen N, Hobbs BP. Statistical design considerations for trials that study multiple indications. Stat Methods Med Res 2021;30:785-98. [PMID: 33267746 DOI: 10.1177/0962280220975187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Taghizadeh H, Zöchbauer-Müller S, Mader RM, Müllauer L, Klikovits T, Bachleitner-Hofmann T, Hoda MA, Prager GW. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. Thorac Cancer 2020;11:1979-88. [PMID: 32438515 DOI: 10.1111/1759-7714.13491] [Reference Citation Analysis]
85 Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov 2018;17:183-96. [PMID: 29217837 DOI: 10.1038/nrd.2017.226] [Cited by in Crossref: 147] [Cited by in F6Publishing: 113] [Article Influence: 29.4] [Reference Citation Analysis]
86 Grayling MJ, Dimairo M, Mander AP, Jaki TF. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. J Natl Cancer Inst 2019;111:1255-62. [PMID: 31218346 DOI: 10.1093/jnci/djz126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
87 Lai TL, Sklar M, Weissmueller NT. Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. Statistics in Biopharmaceutical Research 2021;13:133-46. [DOI: 10.1080/19466315.2020.1814403] [Reference Citation Analysis]
88 Cox S, Rousseau-tsangaris M, Abou-zeid N, Dalle S, Leurent P, Cutivet A, Le H, Kotb S, Bogaert B, Gardette R, Baran Y, Holder J, Lerner L, Blay J, Cambrosio A, Tredan O, Denèfle P. La médecine de précision en oncologie : challenges, enjeux et nouveaux paradigmes. Bulletin du Cancer 2019;106:97-104. [DOI: 10.1016/j.bulcan.2019.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Bai X, Deng Q, Liu D. Multiplicity issues for platform trials with a shared control arm. Journal of Biopharmaceutical Statistics 2020;30:1077-90. [DOI: 10.1080/10543406.2020.1821703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
90 Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst 2019;111:118-28. [PMID: 30561713 DOI: 10.1093/jnci/djy196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
91 Bernhardt J, Hayward KS, Dancause N, Lannin NA, Ward NS, Nudo RJ, Farrin A, Churilov L, Boyd LA, Jones TA, Carmichael ST, Corbett D, Cramer SC. A Stroke Recovery Trial Development Framework: Consensus-Based Core Recommendations from the Second Stroke Recovery and Rehabilitation Roundtable. Neurorehabil Neural Repair 2019;33:959-69. [PMID: 31674274 DOI: 10.1177/1545968319888642] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
92 Lengliné E, Peron J, Vanier A, Gueyffier F, Kouzan S, Dufour P, Guillot B, Blondon H, Clanet M, Cochat P, Degos F, Chevret S, Grande M, Putzolu J; Transparency Committee of the French National Authority for Health. Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. Lancet Oncol 2021;22:e430-4. [PMID: 34592192 DOI: 10.1016/S1470-2045(21)00337-5] [Reference Citation Analysis]
93 Hobbs BP, Landin R. Bayesian basket trial design with exchangeability monitoring. Stat Med 2018;37:3557-72. [PMID: 29984488 DOI: 10.1002/sim.7893] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
94 Halabi S, Lin CY, Liu A. On the design and the analysis of stratified biomarker trials in the presence of measurement error. Stat Med 2021;40:2783-99. [PMID: 33724513 DOI: 10.1002/sim.8928] [Reference Citation Analysis]
95 Elicin O, Cihoric N, Vlaskou Badra E, Ozsahin M. Emerging patient-specific treatment modalities in head and neck cancer - a systematic review. Expert Opin Investig Drugs 2019;28:365-76. [PMID: 30760055 DOI: 10.1080/13543784.2019.1582642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
96 Michiels S, Wason J. Overestimated treatment effects in randomised phase II trials: What's up doctor? Eur J Cancer 2019;123:116-7. [PMID: 31678769 DOI: 10.1016/j.ejca.2019.09.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. JCO Precis Oncol 2017;1:PO. [PMID: 32913969 DOI: 10.1200/PO.17.00181] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Asano J, Hirakawa A. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. Pharm Stat 2020;19:975-1000. [PMID: 32779393 DOI: 10.1002/pst.2049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Lee KM, Brown LC, Jaki T, Stallard N, Wason J. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials 2021;22:203. [PMID: 33691748 DOI: 10.1186/s13063-021-05150-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Benstead-Hume G, Wooller SK, Pearl FMG. 'Big data' approaches for novel anti-cancer drug discovery. Expert Opin Drug Discov 2017;12:599-609. [PMID: 28462602 DOI: 10.1080/17460441.2017.1319356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
101 Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Stat Med 2021;40:2893-921. [PMID: 33772843 DOI: 10.1002/sim.8946] [Reference Citation Analysis]
102 Mukherjee A, Grayling MJ, Wason JM. Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. World Neurosurgery 2022;161:316-22. [DOI: 10.1016/j.wneu.2021.07.061] [Reference Citation Analysis]
103 Wang KF, Chen YD, Mo LQ, Zhang Z, Liu YJ, Chen JX, Sui XB, Xie T, Wu SX. Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment. Shijie Huaren Xiaohua Zazhi 2019; 27(7): 459-466 [DOI: 10.11569/wcjd.v27.i7.459] [Reference Citation Analysis]
104 Kesselmeier M, Benda N, Scherag A. Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation. PLoS One 2020;15:e0237441. [PMID: 32797088 DOI: 10.1371/journal.pone.0237441] [Reference Citation Analysis]
105 Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. Contemp Clin Trials Commun 2018;12:1-8. [PMID: 30182068 DOI: 10.1016/j.conctc.2018.08.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
106 Wilking N, Bucsics A, Kandolf Sekulovic L, Kobelt G, Laslop A, Makaroff L, Roediger A, Zielinski C. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. ESMO Open 2019;4:e000550. [PMID: 31798977 DOI: 10.1136/esmoopen-2019-000550] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
107 Zheng H, Wason JMS. Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. Biostatistics 2020:kxaa019. [PMID: 32380518 DOI: 10.1093/biostatistics/kxaa019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Mills EJ, Nsanzimana S. Have clinical trials in HIV finally matured? Lancet HIV 2019;6:e561-3. [PMID: 31371261 DOI: 10.1016/S2352-3018(19)30240-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Schork NJ, Goetz LH. Single-Subject Studies in Translational Nutrition Research. Annu Rev Nutr 2017;37:395-422. [PMID: 28715990 DOI: 10.1146/annurev-nutr-071816-064717] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
110 Narayan VM, Dahm P. The future of clinical trials in urological oncology. Nat Rev Urol 2019;16:722-33. [PMID: 31605037 DOI: 10.1038/s41585-019-0243-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Pileri SA, Vegliante MC, Ciavarella S. Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment. Oncotarget 2019;10:3991-3. [PMID: 31258840 DOI: 10.18632/oncotarget.27013] [Reference Citation Analysis]
112 Dangond F, Donnelly A, Hohlfeld R, Lubetzki C, Kohlhaas S, Leocani L, Ciccarelli O, Stankoff B, Sormani MP, Chataway J, Bozzoli F, Cucca F, Melton L, Coetzee T, Salvetti M. Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. Nat Rev Neurol 2021;17:185-92. [PMID: 33483719 DOI: 10.1038/s41582-020-00446-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Sun LZ, Kang SP, Chen C. Testing monotherapy and combination therapy in one trial with biomarker consideration. Contemp Clin Trials 2019;82:53-9. [PMID: 31201949 DOI: 10.1016/j.cct.2019.06.002] [Reference Citation Analysis]
114 Pohl M, Krisam J, Kieser M. Categories, components, and techniques in a modular construction of basket trials for application and further research. Biom J 2021;63:1159-84. [PMID: 33942894 DOI: 10.1002/bimj.202000314] [Reference Citation Analysis]
115 Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA. Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer 2018;124:4601-9. [PMID: 30289970 DOI: 10.1002/cncr.31769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
116 Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trials 2018;15:149-58. [PMID: 29499621 DOI: 10.1177/1740774518755122] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
117 Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
118 Hobbs BP, Kane MJ, Hong DS, Landin R. Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study. Ann Oncol 2018;29:2296-301. [PMID: 30335125 DOI: 10.1093/annonc/mdy457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
119 Gray CM, Grimson F, Layton D, Pocock S, Kim J. A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. Drug Saf 2020;43:623-33. [PMID: 32440847 DOI: 10.1007/s40264-020-00944-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Tsuchida J, Rothman J, Mcdonald K, Nagahashi M, Takabe K, Wakai T. Clinical target sequencing for precision medicine of breast cancer. Int J Clin Oncol 2019;24:131-40. [DOI: 10.1007/s10147-018-1373-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
121 Leonetti A, Boyd L, Giuliani J, Giovannetti E, Garajová I. Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'. Expert Rev Clin Pharmacol 2019;12:1033-6. [PMID: 31633383 DOI: 10.1080/17512433.2019.1683446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lange S, Sauerland S, Lauterberg J, Windeler J. The Range and Scientific Value of Randomized Trials. Dtsch Arztebl Int 2017;114:635-40. [PMID: 29017690 DOI: 10.3238/arztebl.2017.0635] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
123 Hirakawa A, Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharm Stat 2022. [PMID: 34994060 DOI: 10.1002/pst.2192] [Reference Citation Analysis]
124 Chen N, Lee JJ. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. Stat Methods Med Res 2020;29:2717-32. [DOI: 10.1177/0962280220910186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med 2020;12:8. [PMID: 31937368 DOI: 10.1186/s13073-019-0703-1] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 45.5] [Reference Citation Analysis]
126 Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S. Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Curr Treat Options Oncol 2018;19:11. [PMID: 29488033 DOI: 10.1007/s11864-018-0524-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
127 Li Y, Zhu S, Liu W, Ming J, Wang X, Hu X. Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Ann Hematol 2020;99:1161-76. [PMID: 32333155 DOI: 10.1007/s00277-020-04028-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]